Evidence map›Paper›PMID 25237065›Full record

Trial reportNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2014

Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers.

Eric A J Hoste, Peter A McCullough, Kianoush Kashani, Lakhmir S Chawla, Michael Joannidis, Andrew D Shaw, Thorsten Feldkamp, Denise L Uettwiller-Geiger, Paul McCarthy, Jing Shi and 3 more

2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 141 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 13 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01209169 completednot on this map

Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury

TypeobservationalSponsorAstute Medical, Inc.Ran2010 to 2013Enrolled890ConditionsAcute Kidney Injury
NCT01846884 completednot on this map

Urine Sample Processing Study:Analysis of Fresh Versus Frozen Urine Samples From Critically Ill Subjects

TypeobservationalSponsorAstute Medical, Inc.Ran2012 to 2013Enrolled124ConditionsAcute Kidney Injury
3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 13 syntheses or guidelines pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Clinical prediction models for acute kidney injury.Revista Brasileira de terapia intensiva · 2020
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 4 countries.

Eric A J HosteIntensive Care Unit, Ghent University Hospital, Ghent University, and Research Foundation-Flanders (FWO), Belgium.
Peter A McCulloughBaylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX The Heart Hospital, Plano, TX.
Kianoush KashaniDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Lakhmir S ChawlaDepartment of Medicine, Division of Intensive Care Medicine, and the Division of Nephrology, Washington, DC, Veterans Affairs Medical Center Department of Anesthesiology and Critical Care Medicine, George Washington University, Washington, DC.
Michael JoannidisDepartment of Internal Medicine, ICU, Medical University Innsbruck, Innsbruck, Austria.
Andrew D ShawDepartment of Anesthesia, Vanderbilt University Medical Center, Nashville, TN, USA.
Thorsten FeldkampDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Germany Department of Nephrology and Hypertension, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Denise L Uettwiller-GeigerClinical Laboratory Trials, JT Mather Memorial Hospital, Port Jefferson, NY, USA.
Paul McCarthyCritical Care Medicine, R Adams Cowley Shock Trauma Center, University of Maryland Medical Center, Baltimore, MD, USA.
Jing ShiWalker Biosciences, Carlsbad, CA, USA.
Michael G WalkerWalker Biosciences, Carlsbad, CA, USA.
John A KellumCenter for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Sapphire Investigators
Walker (United States) · USHeart Hospital Baylor Plano · USInnsbruck Medical University · ATJohn T. Mather Memorial Hospital · USMayo Clinic · USResearch Foundation - Flanders · BEUniversity of Duisburg-Essen · DEUniversity of Maryland, Baltimore · USUniversity of Pittsburgh · USVanderbilt University Medical Center · USVeterans Health Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for a test using these markers.

methodsWe derived cutoffs based on sensitivity and specificity for prediction of Kidney Disease: Improving Global Outcomes Stages 2-3 AKI within 12 h using data from a previously published multicenter cohort (Sapphire). Next, we verified these cutoffs in a new study (Opal) enrolling 154 critically ill adults from six sites in the USA.

resultsOne hundred subjects (14%) in Sapphire and 27 (18%) in Opal met the primary end point. The results of the Opal study replicated those of Sapphire. Relative risk (95% CI) in both studies for subjects testing at ≤0.3 versus >0.3-2 were 4.7 (1.5-16) and 4.4 (2.5-8.7), or 12 (4.2-40) and 18 (10-37) for ≤0.3 versus >2. For the 0.3 cutoff, sensitivity was 89% in both studies, and specificity 50 and 53%. For 2.0, sensitivity was 42 and 44%, and specificity 95 and 90%.

conclusionsUrinary [TIMP-2]•[IGFBP7] values of 0.3 or greater identify patients at high risk and those >2 at highest risk for AKI and provide new information to support clinical decision-making. CLINICAL TRIALS REGISTRATION: Clintrials.gov # NCT01209169 (Sapphire) and NCT01846884 (Opal).

Indexed as

Acute Kidney InjuryAgedBiomarkersCell Cycle CheckpointsFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding ProteinsMaleMiddle AgedPredictive Value of TestsROC CurveTissue Inhibitor of Metalloproteinase-2Biomarkersinsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2acute kidney injuryacute renal failurebiomarkersinsulin-like growth factor binding protein (IGFBP)7 and tissue inhibitor of metalloproteinases (TIMP)-2sensitivity and specificity (MeSH)

Identifiers

PMID25237065
PMCPMC4209880
OpenAlexW2158575236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.